Artelo Biosciences, Inc.
ARTL· Nasdaq
ARTLArtelo Biosciences, Inc.
Filed Aug 12, 2026 · 10-Q · 43 days after period end · 0001640334-26-001323
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$2.43M | -$3.22M | -$2.43M | -$1.60M |
| EPS Diluted | -$0.89 | -$16.86 | -$4.52 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Artelo Biosciences, Inc. · CIK 1621221 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 12, 2026 · 43 d after period end
